Signaling lymphocytic activation molecule family member 6 (SLAMF6)

Signaling lymphocytic activation molecule family member 6 (SLAMF6) is a type I transmembrane receptor belonging to the SLAM/CD2 subfamily of the immunoglobulin superfamily[7][1][5]. Expressed primarily on hematopoietic cells (T cells, B cells, NK cells), SLAMF6 has an extracellular domain comprising IgV- and C2-like regions and a cytoplasmic tail containing two immunoreceptor tyrosine-based switch motifs (ITSMs) essential for downstream signaling[3][5][2]. It mediates homophilic interactions, serving as both ligand and receptor, and modulates immune responses by co-activating or inhibiting lymphocyte functions depending on cellular context and associated adaptor proteins such as SAP and EAT-2[7][3][8]. SLAMF6 is implicated in cancer, congenital immunodeficiencies, and general immune regulation, making it a candidate for biomarker analysis and therapeutic targeting in immunology and oncology research[2][5][6][7][3].

Other names

CD352Ly108 (mouse ortholog)KALIKALIbNTB-ANTBASF2000

Drug candidates and experimental antibodies typically aim to modulate SLAMF6 signaling to enhance or inhibit immune responses (e.g., co-stimulatory or inhibitory modulation of T cell and NK cell function)